Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab

OncoImmunology

Volumn 4, Issue 7, 2015, Pages 1-2

  Ni, Xiao ^a   Langridge, Timothy ^a   Duvic, Madeleine ^a  

^a University of Texas Health Science Center at Houston   (United States)

Author keywords

Chemokine receptor; Cutaneous T cell lymphoma; Mogamulizumab; Monoclonal antibody; Mycosis fungoides; Regulatory T cells; S zary syndrome; Targeted therapy

Indexed keywords

CHEMOKINE RECEPTOR CCR4; MOGAMULIZUMAB; TICILIMUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CUTANEOUS T CELL LYMPHOMA; HUMAN; IMMUNE RESPONSE; MYCOSIS FUNGOIDES; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SEZARY SYNDROME; THROMBOCYTE ACTIVATION;

EID: 84944454410     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1011524     Document Type: Article

References (10)

1. Ishii T. [Development of an anti-CCR4 antibody, mogamulizumab, the first approved antibody made by POTELLIGENT((R)) technology]. Nihon Yakurigaku Zasshi 2013; 142:167-71; PMID:24107520; http://dx.doi.org/10.1254/fpj.142.167
2. Ni X, Jorgensen JL, Goswami M, Challagundla P, Decker WK, Kim YH, Duvic MA. Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome. Clin Cancer Res 2015; 21:274-85; PMID:25376389
3. Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood 2015; 125:1883-9.
4. Kim YH, Pinter-Brown L, Foss F, Sokol L, Jorgensen JL, Spitalny GL, et al. CO26. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. Melanoma Res 2011; 21:e15-e60; http://dx.doi.org/10.1097/01.cmr.0000399460.48119.fe
5. Jones D, O'Hara C, Kraus MD, Perez-Atayde AR, Shahsafaei A, Wu L, Dorfman DM. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood 2000; 96:685-90; PMID:10887135
6. de Rezende LC, Silva IV, Rangel LB, Guimaraes MC. Regulatory T cell as a target for cancer therapy. Arch Immunol Ther Exp 2010; 58:179-90; PMID:20373146; http://dx.doi.org/10.1007/s00005-010-0075-0
7. Andersen MH. The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia 2014; 28:1784-92; PMID:24691076; http://dx.doi. org/10.1038/leu.2014.108
8. Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, Ezoe S, Kanakura Y, Sato E, Fukumori Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3CCD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A 2013; 14:14; PMID:24127572
9. Ni X, Richmond HM, Liao XM, Decker WK, Shiue LH, Shpall EJ, Duvic M. Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA. J Invest Dermatol 2008; 128:2631-9; PMID:18480841; http://dx.doi.org/10.1038/jid.2008. 125
10. Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WYZ, Morales A, Abdulla F, Xing L, Navi D, et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood 2012; 119:355-63; PMID:22045986; http://dx.doi. org/10.1182/blood-2011-05-355222